MOH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Molina Healthcare Inc (MOH) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has shown a recent surge in price and exceeded analyst expectations in Q1 adjusted EPS, the overall financial performance and analyst sentiment indicate significant risks. The company's revenue and net income have dropped substantially YoY, and analysts have largely downgraded their price targets. The technical indicators suggest the stock is overbought, and there are no strong proprietary trading signals to justify an immediate buy.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 92.841, signaling the stock is overbought. Moving averages are converging, suggesting potential price consolidation. Key resistance levels are at 179.175, with support at 143.925.
The company exceeded Q1 adjusted EPS expectations with $2.35 per share and reaffirmed its 2026 guidance. The stock surged 14.18% recently, showing positive market reaction.
Revenue declined by 3.15% YoY, and net income dropped by 95.30% YoY. Analysts have largely downgraded the stock, citing concerns over Medicaid enrollment declines, elevated medical cost trends, and revenue volatility. Technical indicators suggest the stock is overbought.
In Q1 2026, revenue dropped to $10.8 billion (-3.15% YoY), net income fell to $14 million (-95.30% YoY), and EPS decreased to $0.27 (-95.04% YoY). Gross margin also declined to 13.77% (-5.23% YoY).
Most analysts have downgraded the stock or reduced price targets, citing concerns over Medicaid pressures, revenue volatility, and elevated medical costs. Current price targets range from $109 to $180, with a mix of Neutral, Hold, and Underperform ratings.
